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Abstract
Background: Our objective is to determine the activity of the antioxidant defense system at admission in patients
with early onset first psychotic episodes compared with a control group.
Methods: Total antioxidant status (TAS) and lipid peroxidation (LOOH) were determined in plasma. Enzyme
activities and total glutathione levels were determined in erythrocytes in 102 children and adolescents with a first
psychotic episode and 98 healthy controls.
Results: A decrease in antioxidant defense was found in patients, measured as decreased TAS and glutathione
levels. Lipid damage (LOOH) and glutathione peroxidase activity was higher in patients than controls. Our study
shows a decrease in the antioxidant defense system in early onset first episode psychotic patients.
Conclusions: Glutathione deficit seems to be implicated in psychosis, and may be an important indirect biomarker
of oxidative stress in early-onset schizophrenia. Oxidative damage is present in these patients, and may contribute
to its pathophysiology.
Background
Oxidative stress-induced impairment of neuronal processes
has been reported to be involved in neurodegeneration [1]
and also in the pathophysiology of neuropsychiatric
diseases such as schizophrenia [2-6]. It represents an
imbalance between the oxidant molecules and the anti-
oxidant defense system, and generally occurs as a con-
sequence of increased production of reactive oxygen
species (ROS), or when the antioxidant defense system
is inefficient.
The primary antioxidant cellular defense is enzymatic
involving superoxide dismutase (SOD), catalase (CAT)
and glutathione peroxidase (cGPx), which are constitu-
tively expressed in all tissues. Glutathione (GSH) is the
main non-enzymatic cellular antioxidant, regulated by
two enzymes, glutathione peroxidase and glutathione
reductase, which play a critical role in protecting cells
from damage by ROS generated by dopamine metabo-
lism. However, there are conflicting data in the litera-
ture on the activities or levels of antioxidant enzymes in
bipolar disorder [7] and schizophrenia. SOD activity in
erythrocytes of schizophrenia patients has been reported
to be increased [8-11], decreased [12-16] or unchanged
[17-19]. cGPx activities have been reported to be
unchanged [6,10,12,14,18] but also increased [8,20] or
decreased [15,21], and CAT activity has been found
unchanged [14,18,19], increased [13,22] and decreased
[10,23]. SOD levels have been reported to be increased
in plasma [24] and in brain tissues [9]. Some authors
suggest the importance of measuring the total antioxi-
dant status (TAS) in some mental diseases [21-23]. The
early studies of Golse et al. [24-26] founded altered the
levels of SOD and cGPx in children with early-onset
psychosis.
To our knowledge there are few published studies that
have evaluated the oxidative balance in psychosis with
an early age of onset, which has been associated with a
more severe form of the disease than the adult-onset
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form. Thus, child- and adolescent-onset first episode
psychosis needs to be further studied in order to identify
its specific features, differential diagnosis, treatment of
choice and outcome [27,28].
Our goal is to assess oxidative stress at the peripheral
level using measures that could serve as an index of the
pathophysiological changes occurring in the brain of
patients with early-onset first psychotic episodes of
short duration. We hypothesize that patients with early
psychosis will have increased oxidative stress in compar-
ison with a healthy control group.
Methods
Subjects
The Child and Adolescent First-Episode Psychosis
Study (CAFEPS) was a case-control study that included
110 patients with first-episode psychosis (FEP) and a
history of less than 6 months of psychotic symptoms,
and 98 healthy controls. Of this sample, 102 patients
and 95 controls had blood samples available for deter-
mining antioxidant status and were included in the
present study. Diagnosis was confirmed according to
the DSM-IV criteria [29], using the Kiddie Schedule
for Affective Disorders and Schizophrenia, Present and
Lifetime version (K-SADS-PL) [30], Spanish translation
[31] at admission and according to the DSM-IV cri-
teria at one year follow-up. In the analyses, the pro-
blem of diagnostic instability was avoided by grouping
the patients according to their confirmed diagnosis at
one-year follow-up. The study design and recruitment,
and the clinical and demographic characteristics of the
sample have been described elsewhere [32]. Clinical
symptoms were assessed using the following scales: the
Positive and Negative Symptoms Scale (PANSS), the
Hamilton Depression Rating Scale (HDRS)-21, the
Young Mania Rating Scale (YMRS) and the Global
Assessment Functioning (GAF). Neither the patients
nor the control group had participated in heavy exer-
cise or had fasted during the week before study entry.
The study was approved by the Ethics and Clinical
Research Boards of all the Hospitals involved in the
study. Parents or legal representatives gave written
informed consent and participants assented to partici-
pate in the study.
Methods
Blood samples were collected in heparin-containing
tubes immediately after enrolment and processed fol-
lowing standard procedures. Blood cells and plasma
were immediately frozen and stored at -80°C until analy-
sis. All samples were analyzed in a single batch. Oxida-
tive stress was evaluated by measuring primary
enzymatic antioxidant defense (cellular glutathione per-
oxidase, catalase and superoxide dismutase activities)
and plasma levels of total antioxidants, glutathione and
lipid peroxidation. Total antioxidant status (TAS) and
lipid peroxidation were determined by standardized
spectrophotometric assays (Bioxytech) in plasma. Briefly,
the TAS assay [33] relies on the ability of antioxidants
present in plasma to inhibit the oxidation of ABTS
(2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonicacid)),
which is monitored by reading the absorbance at
600 nm. Lipid peroxidation was measured using an
assay for lipid hydroperoxides (LOOHs), which is based
on the oxidation of ferrous ions to ferric ions by hydro-
peroxides under acidic conditions [34]. Enzyme activities
and total GSH levels were also determined by standar-
dized spectrophotometric assays in haemolysates of ery-
throcytes. Total GSH was measured using the Bioxytech
GSH-420 assay kit, which uses a method based on the
formation of a chromophoric thione by specific elimina-
tion of GSH-thioether; the absorbance measured at
420 nm is directly proportional to the total GSH con-
centration. The assay for measuring CAT activity
involved a two step process: (1) a sample containing cat-
alase was incubated in the presence of a known concen-
tration of hydrogen perioxide (H2O2); (2) the remaining
hydrogen peroxide in the reaction mixture facilitated an
oxidative coupling reaction and the resulting quinonei-
mine dye (which correlates to the amount of hydrogen
peroxide) was measured at 520 nm [35]. cGPx enzyme
activity was determined using the method described by
Paglia and Valentine in 1967 [36], where the oxidation
of NADPH to NADP+ was monitored by a decrease in
absorbance at 340 nm. SOD activity determination [37]
was based on the SOD-mediated increase in the rate of
auto-oxidation of a tetracyclic catechol in an aqueous
alkaline solution to yield a chromophore with maximum
absorbance at 525 nm. All the assays were performed in
a diode-array detector coupled to a thermostatically-
controlled water bath.
Statistical analyses
Statistical analyses were carried out with SPSS v14.0
(Statistical Package for the Social Sciences, Chicago,
USA). For descriptive purposes, the continuous variables
were expressed as means ± standard deviation (SD);
ranges and percentages were used to describe the cate-
gorical variables.
To perform the bivariate analyses, Mann-Whitney U
tests were used for continuous variables and contin-
gency tables for categorical variables (c2 or Fisher’s
exact test if n≤5 per cell). To assess age differences
between diagnostic groups, Kruskal-Wallis H tests were
used. The associations between continuous variables
were calculated using nonparametric (Spearman) corre-
lations. Significance was defined as two-tailed p < 0.05
at stated degrees-of-freedom (df).
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Results
Sample characteristics
Age and gender distributions of the subjects did not dif-
fer between patients and controls or between the differ-
ent diagnostic subgroups of patients (Table 1). To avoid
diagnostic instability, the diagnostic spectra were con-
firmed after one year of follow-up and the patients were
grouped as follows: schizophrenia spectrum disorders
(SCH) (48.04%), which includes schizophrenia, schizo-
phreniform and schizoaffective disorders; psychotic dis-
orders not otherwise specified (PNOS) (24.51%);
psychotic bipolar disorder (BIP) (17.65%); and depressive
disorder with psychotic symptoms (DEP) (9.80%). When
the blood samples were collected at admission, 42
patients had been receiving treatment with antipsychotic
medication for some days: 37 patients took atypical anti-
psychotics and the other 5 took typical antipsychotics.
Comparison of the oxidative stress variables and LOOH
levels between the treated and drug-free patient groups
showed no significant differences (TAS: U = 1303.500,
p = 0.814; LOOH: U = 653.500, p = 0.978; GSH: U =
1138.000, p = 0.136; cGPx: U = 932.000, p = 0.669; CAT:
U = 1080.000, p = 0.429; SOD: U = 1169.500, p = 0.127).
Oxidative stress variables of patients versus control
subjects
There were no sex differences between patients and
controls for any of the oxidative stress parameters
assessed (data not shown). When the whole sample was
considered together, there were no significant associa-
tions between any of the oxidative stress variables and
tobacco use, with subjects being classified as smokers if
they reported using tobacco on a daily basis. However,
there was a significant association between age and total
antioxidant status (Spearman Rho = -0.252, p < 0.001).
Analyses of the oxidative stress variables revealed a
decrease in antioxidant defense in FEP patients versus
the control group, measured as decreased TAS in
plasma and decreased GSH levels in erythrocyte lysates
of the blood samples taken at admission. In addition,
lipid damage measured as LOOHs (μM) was signifi-
cantly higher in patients at admission than in control
subjects. Regarding enzyme activities, only cGPx activity
(U/mL) was higher in patients than in controls, with the
activity of CAT and SOD being similar in both groups
of subjects (Table 2).
To determine whether changes in the antioxidant
defense system were associated with membrane damage,
we examined the correlation between LOOH levels
and oxidative stress variables and found a significant
correlation between LOOH levels and SOD (Rho =
-0.190, p = 0.018).
When the oxidative stress variables were compared
between controls and patients in the different diagnostic
groups (Table 3), TAS was significantly lower in all the
diagnostic groups, except the DEP group. Examining
between-diagnostic groups differences in the oxidative
stress variables, we found a significant between-group
difference for TAS, with lower levels in the SCH and
BIP groups (K = 25.620, p < 0.001). None of the other
variables showed a between-diagnostic group difference.
However, as shown in Table 3, GSH levels were lower
only in SCH patients than in controls and lipid hydro-
peroxides (LOOH levels) were significantly higher only
in the BIP group compared with the control group.
For enzyme activities, cGPx activity was significantly
enhanced in the SCH and BIP groups. For CAT and
SOD, there were no significant differences between
patients and the control group or among the different
diagnostic groups.
We found no association between any of the oxidative
stress variables and the following clinical symptoms:
positive symptoms (PANSS positive), negative symptoms
(PANSS negative), and depressive symptoms. There was
Table 1 Distribution of controls and patients by age and gender
Controls Patients PNOS-a SCHb DEPc BIPd
N 95 102 25 49 10 18
Age (years)
Mean + SD 15.25 + 0.22 15.61 + 0.26 15.53 + 0.44 15.42 + 0.39 15.82 + 0.45 16.07 + 0.45
Median 16 (9-17) 16 (9-17) 16 (11-17) 16 (9-17) 16.5 (14-17) 16.5 (11-17)
Statistic 4224.51 (U Mann-Whitney) 4.57 (Kruskal-Wallis)
p-value 0.109 0.335
Gender (male)
Frequency 61 (64.2%) 70 (66.7%) 14 (56%) 38 (77.6%) 7 (70%) 11 (61.1%)
Statistic 0.43 Fisher
p-value 0.548 0.350
aPNOS: Psychotic disorder not otherwise specified, bSCH: Schizophrenia spectrum disorder, cDEP: Depressive disorder with psychotic symptoms, dBIP: Psychotic
bipolar disorder.
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a negative correlation between manic symptoms (YMRS)
and TAS (r = -0.255), and a positive correlation between
global functioning and TAS (r = 0.235).
Discussion
The antioxidant defense system seems to be decreased
in our population of children and adolescents with a
first early onset psychotic episode and who were either
treatment-naïve or had been treated with antipsychotics
for only a short time when the blood samples were
taken at admission. In particular, we found a decreased
total antioxidant status and lower GSH levels in patients
compared to healthy controls. Furthermore, compared
with the control group, TAS was significantly lower in
each of the three main diagnostic groups (psychotic dis-
order not otherwise specified, bipolar disorder and schi-
zophrenia), but GSH was significantly lower only in the
schizophrenia group. Moreover, for the oxidative stress
variables measured, a between-diagnostic group differ-
ence was significant only for TAS, with the lowest TAS
levels in the schizophrenic and bipolar patients. From
the baseline data it appears that patients with more
severe and chronic diseases (SCH and BIP) have more
oxidative stress than those with acute psychosis. Indeed,
it must be taken into account that although the oxida-
tive data shown were obtained at baseline, the diagnoses
were only confirmed during the follow-up. These preli-
minary findings suggest that antioxidant problems may
be a function of diagnosis, in this case schizophrenia
and bipolar disorder.
Lipid oxidative damage seems to be increased in early
first psychotic episode patients, measured as elevated
levels of lipid hydroperoxides (LOOHs); the activity of
cGPx is also elevated in patients compared with healthy
controls. When comparing the patient subgroups by
confirmed diagnoses with the control group, only bipo-
lar patients had elevated LOOHs.
There is no bias in the results due to treatment use,
because there were no differences in oxidative stress
when we compared the patients who were treatment-
naïve with those who had received antipsychotic treat-
ment before admission. Previously, it has been stated
that psychopharmacological treatment can partially
Table 2 Oxidative stress variables for the control group
and patients in blood samples taken at admission
Variables in blood
samples
Control N = 94
Patient N = 102
Mean SD U Mann-
Whitney
p-value
Total Antioxidant Status
(mM)
2787.54 <0.001
Control (N = 94) 1.26 0.05
Patient (N = 102) 0.95 0.35
Glutathione (μM) 4194 0.001
Control (N = 93) 394.12 15.91
Patient (N = 90) 324.38 13.54
Lipid Hydroperoxides
(μM)
2369.53 0.018
Control (N = 82) 6.17 0.47
Patient (N = 74) 9.15 1.20
Glutathione Peroxidase
(mU/mL)
3421.56 0.033
Control (N = 93) 913.06 59.98
Patient (N = 90) 1028.91 49.55
Catalase (U/mL) 3783.54 0.262
Control (N = 94) 10708.92 4715.01
Patient (N = 110) 10473.27 4633.22
Superoxide Dismutase
(U/mL)
3700 0.176
Control (N = 94) 5079.55 2938.49
Patient (N = 110) 6072.4 2914.30
Table 3 Oxidative stress variables for patients in the different diagnostic groups versus the control group
N Mean SD U Mann-hitney p N Mean SD U Mann-Whitney p
TAS (mM) GSH (μM)
Control group 94 1.26 0.05 93 394.11 15.90
SCHb 49 0.91 0.04 1193.50 < 0.001 43 308.34 20.06 1317.50 0.005
PNOS-a 25 0.99 0.09 622 0.002 21 327.62 29.21 555 0.195
BIPd 18 0.88 0.06 290.50 0.001 17 347.44 24.15 530.50 0.606
DEPc 10 1.16 0.14 232.50 0.501 9 350.27 45.23 245.50 0.841
LOOH (μM) cGPX (mU/mL)
Control group 82 6.17 0.47 93 912.96 59.93
SCHb 33 10.06 2.50 1431 0.161 43 1068.37 61.63 2283.50 0.015
PNOS-a 17 6.03 0.87 641 0.856 21 620.73 135.46 823.50 0.734
BIPd 15 10.88 1.58 713.50 0.004 17 1142.08 112.88 831 0.031
DEPc 9 8.82 1.60 328.50 0.083 9 728.812 80.62 228 0.447
aPNOS: Psychotic disorder not otherwise specified, bSCH: Schizophrenia spectrum disorder, cDEP: Depressive disorder with psychotic symptoms, dBIP: Psychotic
bipolar disorder.
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reverse oxidative stress [38]. However, in our patient
sample, treatment was used for only a short period
before hospitalization, and we have not yet performed a
longitudinal prospective analysis of the sample. We
found a relationship between age and oxidative stress
when the patients and controls were considered
together. However, we cannot conclude that the older
the age, the higher oxidative stress, as our older patients
were adolescents. Other studies have not found any age-
related differences in total antioxidant status in healthy
volunteers [39].
A defect in antioxidant protection seems to be a com-
mon feature of patients with a first psychotic episode,
but has been little explored so far in early onset psycho-
sis and patients who have been psychotic for only a
short time. This defect should be taken into account
when developing neuroprotective treatments.
Despite the conflicting data found previously [40-43],
abnormalities in antioxidant enzyme activities are fre-
quently found in patients diagnosed with psychosis or
bipolar disorder. This imbalance in enzyme activities
reduces the efficacy of the cellular antioxidant defense,
which requires a proper balance of antioxidant enzymes,
and contributes to brain pathology [44]. Indeed, we
found a significant correlation between SOD and LOOH
levels indicating that oxidative stress is probably produ-
cing lipid damage. It has been taken into account that
the brain contains almost no catalase and less cGPx
than other tissues. Although these enzymes may serve
as peripheral indicators of oxidative stress, this makes
our results for GSH levels and SOD activity more
interesting.
The GSH deficit found in this study and in previous
reports [15,40,45-47] may be involved in membrane per-
oxidation and microlesions related to dopamine, which
seem to be increased in psychosis, and suggest that GSH
may be a possible indirect indicator of damage in neuro-
nal membranes [48-52]. Anomalies in GSH metabolism
were also supported by the low expression of the gene of
the key GSH-synthesizing enzyme, glutamate cysteine
ligase modifier subunit, in patient fibroblasts [53]. More-
over, inhibition of brain glutathione synthesis and dopa-
mine uptake in developing rats induces long-term
cognitive deficits in adulthood [54]. Therefore, it seems
that dopamine, which has a neurotoxic potential, contri-
butes to cellular oxidative stress, which can be exacer-
bated if glutathione synthesis is compromised [55]. In
addition, the concentrations of glutathione and one of its
metabolites, glutamylglutamine, are reduced in the cere-
brospinal fluid of drug-free patients [56]. An animal
model of schizophrenia has recently been proposed
where a redox imbalance during postnatal development
induces abnormalities in cortical development [57]. Also,
a recent study performed in cultured fibroblasts of
patients with schizophrenia found impaired genetic and
functional capacity to synthesize GSH under conditions
of oxidative stress in schizophrenic patients [58]. These
converging data, in agreement with our results in child
and adolescent patients, indicate that psychosis is asso-
ciated with an important brain glutathione deficit. One
question not answered by this study is why early-onset
bipolar patients (who also have dopamine metabolism
alterations) do not show a significant GSH deficit. It is
possible that patients diagnosed with bipolar disorder
share some etiological and physiopathological mechan-
isms with schizophrenia, but not all. Indeed, patients
with bipolar disorder usually have less cognitive dysfunc-
tion in the long term and better prognosis than patients
with schizophrenia. In fact, it could be hypothesized that
different etiological mechanisms converge into precipitat-
ing a psychotic episode in an adolescent, and only in
individuals with a limited GSH synthesis capacity, after
which the psychotic episode develops into a degenerating
condition that we call schizophrenia. This could be tested
by analyzing glutathione in high risk populations that are
subsequently followed up.
In our patient group, the presence of manic symptoms
was associated with lower antioxidant capacity. Pre-
viously, Andreazza et al. [59] demonstrated that DNA
damage, probably due to oxidative stress, was increased
in mania patients and was related to severity of mania.
We also found that antioxidant defense was related to
global functioning.
Oxidative stress has been related to DNA damage, and
it has been suggested that psychopharmacological treat-
ment can partially reverse oxidative stress. As oxidative
stress could be a marker of severity in patients with
medical conditions such as atherosclerosis [60] or dia-
betes [61,62], long-term investigations should determine
whether it is also a marker of severity in patients with
psychosis. It is possible that oxidative stress could also
mediate the vascular damage of patients with psychosis
as it has been established that patients with psychosis
are at higher risk of developing cardiovascular diseases
[63] and diabetes [64].
Although we should be cautious, our findings support
the possibility of using peripheral markers of oxidative
and antioxidative balance in patients with first-episode
psychosis, taking into account the special sensitivity of
the brain to oxidative damage [65].
This study has some limitations. Data are cross-
sectional, diagnostic subgroups are relatively small, and
it was difficult to establish in advance a sample size to
perform the data analyses because of the paucity of stu-
dies with similar design characteristics; nevertheless, our
patient sample is one of the largest reported to date.
A second limitation is the type of recruitment centers;
the majority was hospital settings with an inpatient
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facility and this may represent a bias towards the inclu-
sion of more severe cases, making it difficult to general-
ize the results to less severe ones. Because the data
presents changes in peripheral blood, further work is
needed to determine if such changes adequately reflect
changes in the brain and of mental state. The strengths
of the study are the uniformity in age with an early
onset and first episode of all psychoses, and the exis-
tence of a control group.
Conclusions
In summary, our study shows a decrease in the antioxi-
dant defense system in early onset first episode psycho-
tic patients. Glutathione deficit seems to be implicated
in psychosis, and may be an important indirect biomar-
ker of oxidative stress in schizophrenia. Oxidative
damage is present in these patients and, although it may
not be the main cause of psychosis, it may contribute to
the pathophysiology and account for a deteriorating
course and poor outcome in this early onset group.
Because all the patients in the study had a first early-
onset psychotic episode, the data indicate ongoing oxi-
dative injury at onset of psychosis. Moreover, because
the onset of psychotic disorders during childhood and
adolescence has a devastating negative impact on nor-
mal development and functioning [66], our results pro-
vide support for further study of the possible role of
antioxidants as neuroprotective therapeutic strategies for
schizophrenia from early stages [67]. Data from the
longitudinal study will clarify the possible utility of per-
ipheral markers of oxidative stress as prognostic factors
and also the effect of antipsychotic drugs on oxidative
stress.
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